Cargando…
Cancer Immunotherapies: What the Perioperative Physician Needs to Know
PURPOSE OF REVIEW: For patients with cancer, treatment may include combination therapy, including surgery and immunotherapy. Here, we review perioperative considerations for the patient prescribed immunotherapeutic agents. RECENT FINDINGS: The perioperative period is a poignant moment in the journey...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9056594/ https://www.ncbi.nlm.nih.gov/pubmed/35141856 http://dx.doi.org/10.1007/s11912-022-01202-6 |
_version_ | 1784697697551253504 |
---|---|
author | Ackerman, Robert S. Muncey, Aaron R. Aldawoodi, Nasrin N. Kotha, Rohini Getting, Rosemarie E. Garcia |
author_facet | Ackerman, Robert S. Muncey, Aaron R. Aldawoodi, Nasrin N. Kotha, Rohini Getting, Rosemarie E. Garcia |
author_sort | Ackerman, Robert S. |
collection | PubMed |
description | PURPOSE OF REVIEW: For patients with cancer, treatment may include combination therapy, including surgery and immunotherapy. Here, we review perioperative considerations for the patient prescribed immunotherapeutic agents. RECENT FINDINGS: The perioperative period is a poignant moment in the journey of a patient with cancer, potentially deemed most influential compared to other moments in the care continuum. Several immunotherapeutic medications have been employed near the time of surgery to potentially increase effectiveness. Of the various drug classes, including immune checkpoint inhibitors, cytokines, toll-like receptor agonists, and oncolytic viruses, among others, several notable immune-related adverse effects were noted. They range from minor effects to more serious ones, such as renal failure, myocarditis, and tumor growth. SUMMARY: Surgery and immunotherapy are often employed in combination for primary treatment and prevention of cancer recurrence. Careful review and consideration of the pharmacokinetics, pharmacodynamics, and toxicities of immunotherapy benefit the perioperative physician and their patients. |
format | Online Article Text |
id | pubmed-9056594 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-90565942022-05-02 Cancer Immunotherapies: What the Perioperative Physician Needs to Know Ackerman, Robert S. Muncey, Aaron R. Aldawoodi, Nasrin N. Kotha, Rohini Getting, Rosemarie E. Garcia Curr Oncol Rep Anesthesiology and Critical Care (JP Cata, Section Editor) PURPOSE OF REVIEW: For patients with cancer, treatment may include combination therapy, including surgery and immunotherapy. Here, we review perioperative considerations for the patient prescribed immunotherapeutic agents. RECENT FINDINGS: The perioperative period is a poignant moment in the journey of a patient with cancer, potentially deemed most influential compared to other moments in the care continuum. Several immunotherapeutic medications have been employed near the time of surgery to potentially increase effectiveness. Of the various drug classes, including immune checkpoint inhibitors, cytokines, toll-like receptor agonists, and oncolytic viruses, among others, several notable immune-related adverse effects were noted. They range from minor effects to more serious ones, such as renal failure, myocarditis, and tumor growth. SUMMARY: Surgery and immunotherapy are often employed in combination for primary treatment and prevention of cancer recurrence. Careful review and consideration of the pharmacokinetics, pharmacodynamics, and toxicities of immunotherapy benefit the perioperative physician and their patients. Springer US 2022-02-10 2022 /pmc/articles/PMC9056594/ /pubmed/35141856 http://dx.doi.org/10.1007/s11912-022-01202-6 Text en © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Anesthesiology and Critical Care (JP Cata, Section Editor) Ackerman, Robert S. Muncey, Aaron R. Aldawoodi, Nasrin N. Kotha, Rohini Getting, Rosemarie E. Garcia Cancer Immunotherapies: What the Perioperative Physician Needs to Know |
title | Cancer Immunotherapies: What the Perioperative Physician Needs to Know |
title_full | Cancer Immunotherapies: What the Perioperative Physician Needs to Know |
title_fullStr | Cancer Immunotherapies: What the Perioperative Physician Needs to Know |
title_full_unstemmed | Cancer Immunotherapies: What the Perioperative Physician Needs to Know |
title_short | Cancer Immunotherapies: What the Perioperative Physician Needs to Know |
title_sort | cancer immunotherapies: what the perioperative physician needs to know |
topic | Anesthesiology and Critical Care (JP Cata, Section Editor) |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9056594/ https://www.ncbi.nlm.nih.gov/pubmed/35141856 http://dx.doi.org/10.1007/s11912-022-01202-6 |
work_keys_str_mv | AT ackermanroberts cancerimmunotherapieswhattheperioperativephysicianneedstoknow AT munceyaaronr cancerimmunotherapieswhattheperioperativephysicianneedstoknow AT aldawoodinasrinn cancerimmunotherapieswhattheperioperativephysicianneedstoknow AT kotharohini cancerimmunotherapieswhattheperioperativephysicianneedstoknow AT gettingrosemarieegarcia cancerimmunotherapieswhattheperioperativephysicianneedstoknow |